HIMS Up 5% After HHS Temporarily Allows Compounding Six PeptidesHims & Hers Health, Inc. Class ABATS:HIMSKalaGhaziShares of Hims & Hers (HIMS) climbed 5% on Wednesday after the Department of Health and Human Services (HHS) said it would temporarily permit compounding pharmacies to produce six popular peptides. The policy shift was viewed by investors as a potential opening for Hims & Hers to expand its peptide-related offerings, although the move is temporary and does not constitute FDA approval of the peptides themselves. Under the new temporary policy, HHS said it will not pursue enforcement action against state-licensed pharmacies, federal facilities, or licensed doctors for compounding six peptides—BPC-157, Epitalon, KPV, MOTS-m, Semax, and TB-500—provided they comply with basic requirements covering ingredient quality, manufacturing standards, safety reporting, labeling, and prescriptions written for individual patients. The policy is intended to remain in place while the FDA completes formal rulemaking to establish the official list of bulk substances that may be used in compounding. HHS also said compounders must report serious adverse events associated with the use of the drugs, as well as product quality issues such as contamination, to the FDA. Compounded drugs are not FDA-approved. How Hims & Hers Is Positioned to Monetize the Move Hims & Hers has already taken steps to prepare for a possible approval or broader acceptance of peptide compounding. The company has secured a peptide facility in California and has been testing ingredients, according to the report. It has also signaled interest in offering products such as sermorelin, glutathione, and NAD+, depending on how final regulatory decisions unfold. Peptides used for recovery, inflammation, sleep, and related wellness goals have attracted strong consumer interest online, even without formal FDA approval. That demand could create a commercial opportunity for companies like Hims & Hers if the regulatory environment allows compounded peptide products to be offered more widely. However, the company has also faced setbacks this year. In late July, the Federal Trade Commission filed a lawsuit alleging deceptive privacy practices involving data sharing with advertising platforms, as well as misleading billing or cancellation practices. In addition, Hims & Hers transitioned earlier this year from offering compounded GLP-1s to branded versions, a change that has pressured margins despite continued subscriber growth. Those issues remain relevant as investors assess how much the peptide policy shift could contribute to the company’s future growth. Hims CEO Andrew Dudum described the news as “encouraging progress.” The stock reaction suggests that investors see the temporary HHS policy as a positive signal for Hims & Hers’ ability to participate in the peptide market, particularly given the company’s prior preparations. Still, the policy is temporary, the FDA’s formal rulemaking process remains ongoing, and compounded drugs do not have FDA approval. As a result, the longer-term commercial impact for Hims & Hers will depend on the final regulatory framework, the company’s ability to meet compounding requirements, and consumer demand for peptide-based wellness products.